Restasis vs Syfovre
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Restasis | US Syfovre | |
|---|---|---|
| Generic name | cyclosporine ophthalmic emulsion | pegcetacoplan |
| Drug class | Calcineurin Inhibitor (Eye Drop) | Complement C3 Inhibitor |
| Treats | Chronic dry eye | Geographic atrophy (advanced dry AMD) |
| Category | Eye Health | Eye Health |
| Manufacturer | AbbVie (Allergan) | Apellis Pharmaceuticals |
| Year approved | 2003 | 2023 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $100M | — |
| Common side effects | Burning sensation, Eye redness, Watery eyes, Blurred vision | Eye discomfort, Floaters, Bleeding in the eye, Increased eye pressure |
Frequently asked questions
Is Restasis or Syfovre better?
Neither is universally "better." Restasis (cyclosporine ophthalmic emulsion) and Syfovre (pegcetacoplan) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Restasis and Syfovre?
Restasis is a Calcineurin Inhibitor (Eye Drop) made by AbbVie (Allergan), while Syfovre is a Complement C3 Inhibitor made by Apellis Pharmaceuticals. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Restasis has the larger estimated TV advertising budget of the two.